Crescent Biopharma (CBIO) Consolidated Net Income (2013 - 2026)
Crescent Biopharma (CBIO) reported Consolidated Net Income of -$23.3 million for Q1 2026, down 53.7% year-over-year from -$50.3 million in Q1 2025, and up 74.24% quarter-over-quarter from -$90.4 million in Q4 2025.
Crescent Biopharma (CBIO) Consolidated Net Income (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 14 years of Consolidated Net Income data on file, last reported at -$23.3 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$23.3 million, down 53.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$160.1 million (down 249.96% YoY), and the FY2025 annual result was -$153.9 million, down 293.67% from the prior year.
- Consolidated Net Income grew to -$23.3 million in Q1 2026 per CBIO's latest filing, from -$90.4 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$2.6 million in Q3 2024 and troughed at -$90.4 million in Q4 2025.
- A 5-year average of -$17.7 million and a median of -$10.7 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income soared 71.41% in 2024, then sank 835.27% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$10.2 million in 2022, then climbed by 11.38% to -$9.1 million in 2023, then plunged by 96.8% to -$17.9 million in 2024, then plunged by 405.94% to -$90.4 million in 2025, then jumped by 74.24% to -$23.3 million in 2026.
- Business Quant data shows CBIO's Consolidated Net Income at -$23.3 million in Q1 2026, -$90.4 million in Q4 2025, and -$24.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -23.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.28 Mn |
| Dec 31, 2025 | -90.40 Mn |
| Sep 30, 2025 | -24.61 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Mar 31, 2025 | -15.15 Mn |
| Dec 31, 2024 | -17.87 Mn |
| Sep 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -10.10 Mn |
| Mar 31, 2024 | -10.74 Mn |
| Dec 31, 2023 | -9.08 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Jun 30, 2023 | -8.26 Mn |
| Mar 31, 2023 | -10.36 Mn |
| Dec 31, 2022 | -10.24 Mn |
| Sep 30, 2022 | -8.52 Mn |
| Jun 30, 2022 | -13.27 Mn |
| Mar 31, 2022 | -14.65 Mn |
| Dec 31, 2021 | -17.42 Mn |
| Sep 30, 2021 | -17.33 Mn |
| Jun 30, 2021 | -14.40 Mn |